drugset / Trial / NCT03811535

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

NCT03811535

Phase 3 Completed 200 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Researchers will test to see how well somapacitan works. The study will also test if somapacitan is safe. Participants will either get somapacitan or Norditropin® - which treatment participants get, is decided by chance. Both participants and the study doctor will know which treatment participants get. The study will last for 4 years. Participants will attend 19 clinic visits and have 1 phone call with the study doctor.

Timeline

Start
2019-05-20
Primary completion
2021-11-10
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatropin Protein / enzyme biologic 0.034 mg/kg Subcutaneous
Subject somapacitan Protein / enzyme biologic 0.16 mg/kg Subcutaneous

Indications